The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.

Regeneron will distribute Inmazeb treatment doses over the course of six years to BARDA.

The judges chose Sheng from a shortlist of seven candidates and highlighted his work in the Taiwanese and global markets while guiding the company through “pivotal changes” that demonstrated his abilities as a “top CEO.”

Cytiva will provide the first FlexFactory to be used in the manufacture of pDNA to Akron Bio.

The approval comes after a Phase III trial that showed Keytruda reduced the risk of disease progression or death by 35%.

Shimadzu, has opened a new branch office in Copenhagen, Denmark.

Cambrex has completed the expansion of its solid form screening and crystallization process development facility in Edinburgh, Scotland.

Oxular has been granted rare pediatric disease and orphan drug designations by the US FDA for its proprietary drug, OXU-003.

The UK's MHRA has joined the Australia-Canada-Singapore-Switzerland (ACSS) Consortium of regulators.

Roche will use Dyno’s CapsidMap platform to develop next-generation adeno-associated virus vectors for gene therapies for central nervous system diseases and liver-directed therapies.

The winners were announced during day seven of CPhI Festival of Pharma.

The company will supply its LIMS to the Walter Reed Army Institute of Research (WRAIR) to support vaccine production programs for COVID-19 at WRAIR’s pilot bioproduction facility.

Virtual Touring allows companies to inspect and visit vendor and contract partner sites remotely during the COVID-19 pandemic.

The unexplained illness in a study participant is being reviewed and evaluated by an independent data safety monitoring board and internal clinical and safety physicians.

The companies are entering into an agreement for the late-stage development and large-scale manufacturing of AZD7442, AstraZeneca’s investigational product for treatment and prevention of COVID-19.

The expansion has doubled Cambrex’s footprint to 15,000 ft2, including an added 3500 ft2 of laboratory space.

Bio/pharma industry leaders support FDA’s newly published EUA guidance for COVID-19 vaccine authorization.

Rentschler will handle the downstream processing to provide highly purified drug substance at its headquarters in Laupheim, Germany.

The partnership aims to provide a platform of hiPSC-based assays, drug discovery technologies, high-throughput screening, and high-content screening.

Purdue University’s Continuity Pharma received a $1.5-million grant from DARPA to develop continuous manufacturing technology for generic drug products.

Under the contract, Pharm-Olam will offer routine and response clinical services for the development of medical countermeasures.

FDA approved the first commercial drug manufactured via Aji Bio-Pharma's proprietary production process.

Schott and Credence MedSystems have formed a strategic collaboration to make syringe injections safer.

Enterprise Therapeutics has announced that its novel TMEM16A potentiator portfolio has been fully acquired by Roche

Independent research performed at the University of St. Andrews in the UK has reportedly demonstrated the effectiveness of Alfacyte in-vitro against SARS-CoV-2.

A complete listing of event dates for CPhI and Pharmapack Europe 2021 has been released.

Following a recent expansion at its Cambridge, MA, facility, the company now houses a new suite of cellular analysis platforms that enhance its exploratory capabilities into oncology, neuroscience, and rare diseases.

The new personal capillary electrophoresis system, Spectrum Compact CE, performs Sanger sequencing and fragment analysis.